| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Reports |
DAVID BERLANA, PHARM.D., is Hospital Pharmacy Specialist; J. M. LLOP, PH.D., PHARM.D., is Hospital Pharmacy Specialist; E. FORT, PHARM.D., is Hospital Pharmacy Specialist; M. B. BADIA, PHARM.D., is Hospital Pharmacy Specialist; and R. JÓDAR, PH.D., PHARM.D., is Hospital Pharmacy Specialist and Director of the Pharmacy Service; Pharmacy Service, Hospital Universitari de Bellvitge, Barcelona, Spain.
Address correspondence to Dr. Berlana at Servei de Farmacia, Hospital Universitari de Bellvitge, Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain (dberlana{at}hosppal.es).
Methods. The efficacy of colistin for treating infections caused by MDR gram-negative microorganisms and the development of renal toxicity were studied in hospitalized adult patients in Spain. Patients treated between January 2001 and October 2001 were included.
Results. Over the study period, 71 courses of inhaled colistin, 12 courses of i.v. or intramuscular (i.m.) colistin, and 2 courses of intrathecal colistin were administered to 80 patients. All were infected by MDR organisms: 69 (86%) by Acinetobacter baumannii and 11 (14%) by Pseudomonas aeruginosa. In 41 patients (51%), the episodes were caused by A. baumannii strains susceptible exclusively to colistin. The causative organisms were cleared in 92% of the patients from whom posttreatment repeat specimens were obtained. The in-hospital mortality rate was 18% (14 patients). There were no significant changes in mean serum urea or creatinine concentrations in patients receiving i.v. or i.m. therapy.
Conclusion. Colistin was used in 80 patients infected with A. baumannii or P. aeruginosa and appeared to be efficacious and safe.
Index terms: Acinetobacter baumannii; Antibiotics; Bacterial infections; Colistin; Kidney diseases; Mortality; Pseudomonas aeruginosa; Resistance; Toxicity
Purpose. The use of colistin for the treatment of infections caused by multiple-drug-resistant (MDR) gram-negative micro-organisms was studied.
This article has been cited by other articles:
|
|
 |
|
  D. Landman, C. Georgescu, D. A. Martin, and J. Quale Polymyxins Revisited Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Peleg, H. Seifert, and D. L. Paterson Acinetobacter baumannii: Emergence of a Successful Pathogen Clin. Microbiol. Rev., July 1, 2008; 21(3): 538 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Oliveira, G. V. B. Prado, S. F. Costa, R. S. Grinbaum, and A. S. Levin Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J. Antimicrob. Chemother., June 1, 2008; 61(6): 1369 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Bergen, J. Li, R. L. Nation, J. D. Turnidge, K. Coulthard, and R. W. Milne Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model J. Antimicrob. Chemother., March 1, 2008; 61(3): 636 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ioannidou, I. I. Siempos, and M. E. Falagas Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis J. Antimicrob. Chemother., December 1, 2007; 60(6): 1216 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Arnold, G. N. Forrest, and K. J. Messmer Polymyxin antibiotics for gram-negative infections Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 819 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. He, D. Kisla, L. Zhang, C. Yuan, K. B. Green-Church, and A. E. Yousef Isolation and Identification of a Paenibacillus polymyxa Strain That Coproduces a Novel Lantibiotic and Polymyxin Appl. Envir. Microbiol., January 1, 2007; 73(1): 168 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ng, I. B. Gosbell, J. A. Kelly, M. J. Boyle, and J. K. Ferguson Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review J. Antimicrob. Chemother., November 1, 2006; 58(5): 1078 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P Holloway, N. G Rouphael, J. B Wells, M. D King, and H. M Blumberg Polymyxin B and Doxycycline Use in Patients with Multidrug-Resistant Acinetobacter baumannii Infections in the Intensive Care Unit Ann. Pharmacother., November 1, 2006; 40(11): 1939 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Shirk, K. R. Donahue, and J. Shirvani Unlabeled uses of nebulized medications. Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1704 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Bergen, J. Li, C. R. Rayner, and R. L. Nation Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1953 - 1958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Falagas, S. K. Kasiakou, S. Tsiodras, and A. Michalopoulos The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin. Med. Res., June 1, 2006; 4(2): 138 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, C. R. Rayner, R. L. Nation, R. Deans, R. Boots, N. Widdecombe, A. Douglas, and J. Lipman Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous Hemodiafiltration Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4814 - 4815. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Katragkou and E. Roilides Successful Treatment of Multidrug-Resistant Acinetobacter baumannii Central Nervous System Infections with Colistin J. Clin. Microbiol., September 1, 2005; 43(9): 4916 - 4917. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
